Nicholas Naclerio has become president of South San Francisco-based ParAllele BioScience and has joined the company’s board of directors. Most recently, he was an independent strategic consultant to life science companies and venture capital groups. Prior to that, he was chief business officer and a senior vice president at Zyomyx. Naclerio holds a PhD from the University of Maryland, a master’s equivalent from the University of Cambridge in England, and a bachelor’s degree from Duke University.
Richard Mason has been promoted to vice president of business development at UK-based Cambridge Antibody Technology and will also join the company’s executive group, replacing Jason Avery. Prior to his promotion, he was director of business alliances at CAT. Mason holds an MBA from the University of Cambridge, and a medical degree from the Medical College of St. Bartholomew’s Hospital in the UK.
In addition, Jane Osbourn has been promoted to vice president for display technology, from director of display technology. She holds a PhD in plant molecular virology from the John Innes Institute in Norwich, UK, and an undergraduate degree in biochemistry from the University of Cambridge.
Robert Joss, dean of the graduate school of business at Stanford University, has joined the board of directors of Agilent Technologies. Prior to joining Stanford, he was the CEO and managing director of Westpac Banking, Australia’s second largest bank. Joss holds an MBA and a PhD from Stanford University as well as a BA in economics from the University of Washington.
Clive Wood will become senior vice president for discovery research and the chief scientific officer of Cambridge, Mass.-based Dyax next month. He joins the company from Wyeth Research, where he was senior director and acting head of inflammation discovery research. Wood holds a bachelor’s degree and a PhD in biochemistry from the University of London.